Discover investment opportunities in Gene Therapy Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Gene Therapy Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Gene Therapy Stocks using our Smart AI Filter.
8 stocks found for "Gene Therapy Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.76 | ±68.4% | -8.1 | 0.00% | |||
2.51 | ±100.0% | -1.1 | 0.00% | |||
2.02 | ±100.0% | -4.6 | 0.00% | |||
2.26 | ±100.0% | -7.6 | 0.00% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
1.34 | ±55.5% | -10.4 | 0.00% | |||
1.92 | ±68.6% | -1.9 | 0.00% | |||
1.98 | ±100.0% | -2.4 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How does CRISPR Therapeutics (CRSP) differentiate itself in the gene therapy industry?
A: CRISPR Therapeutics is a leader in the field of CRISPR/Cas9 gene editing technology, which offers precise editing capabilities. This tech may allow CRSP to develop therapies targeting genetic disorders more effectively than traditional methods. Partnerships with pharmaceutical giants and a strong pipeline enhance its competitive positioning.
Q: What risk factors are associated with investing in NTLA (Intellia Therapeutics)?
A: NTLA leverages CRISPR technology, but risks include regulatory challenges, high R&D costs, and competition from other biotech firms. The gene therapy sector's volatility and potential for ethical concerns also impact NTLA's risk profile.
Q: Why might investors be interested in Beam Therapeutics (BEAM) for long-term growth?
A: BEAM specializes in base editing technology, a promising variation of gene editing. This innovative approach could address diseases untreatable by other methods, positioning BEAM as a potential leader with significant long-term growth prospects.
Q: How does EDIT (Editas Medicine) perform under economic downturns?
A: As a biotech company, EDIT is less sensitive to typical economic cycles than other industries. However, economic downturns can affect funding availability and investor confidence in speculative technologies like gene editing.
Q: What industry trends support investment in Bluebird Bio (BLUE)?
A: Bluebird Bio focuses on gene therapies for severe genetic diseases. The increasing understanding of genetic disorders and advancements in technology support the growth of companies like BLUE, despite high developmental costs.
Q: How is Sangamo Therapeutics (SGMO) addressing clinical trial challenges?
A: Sangamo is mitigating clinical trial risks by leveraging partnerships with larger pharmaceutical companies, which can provide funding and resources. They focus on indications with clear genetic markers, aiming for better trial outcomes.
The U.S. Food and Drug Administration (FDA) on Monday extended its review timeline for REGENXBIO Inc.'s RGNX Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121) for Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome.
Read moreThe consensus price target hints at a 142.7% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read more